Form 13-F position report

LA JOLLA PHARMACEUTICAL CO

Reported by TANG KEVIN C

LJPC CUSIP 503459604 Manager CIK 0001178579

Reported 0 shares, down 240,000 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2022
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 15 Through Q3 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2019-03-31 1543000
2019-06-30 2220000
2019-09-30 2112000
2019-12-31 943000
2020-03-31 1008000
2020-06-30 1022000
2020-09-30 967000
2020-12-31 931000
2021-03-31 1018000
2021-06-30 1027000
2021-09-30 958000
2021-12-31 1116000
2022-03-31 1025000
2022-06-30 766000
2022-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for LA JOLLA PHARMACEUTICAL CO held by TANG KEVIN C.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2022 Reduced 0 -240,000 (-100.0%) 0 $0 2022-11-14
Q2 2022 Unchanged 240,000 0 (0.0%) 99.74% $766,000 2022-08-15
Q1 2022 Unchanged 240,000 0 (0.0%) 99.61% $1,025,000 2022-05-16
Q4 2021 Unchanged 240,000 0 (0.0%) 99.38% $1,116,000 2022-02-14
Q3 2021 Unchanged 240,000 0 (0.0%) 99.17% $958,000 2021-11-15
Q2 2021 Unchanged 240,000 0 (0.0%) 95.09% $1,027,000 2021-08-16
Q1 2021 Unchanged 240,000 0 (0.0%) 94.79% $1,018,000 2021-05-17
Q4 2020 Unchanged 240,000 0 (0.0%) 92.73% $931,000 2021-02-16
Q3 2020 Unchanged 240,000 0 (0.0%) 78.24% $967,000 2020-11-16
Q2 2020 Unchanged 240,000 0 (0.0%) 79.29% $1,022,000 2020-08-14
Q1 2020 Unchanged 240,000 0 (0.0%) 80.13% $1,008,000 2020-05-15
Q4 2019 Unchanged 240,000 0 (0.0%) 11.17% $943,000 2020-02-14
Q3 2019 Unchanged 240,000 0 (0.0%) 75.03% $2,112,000 2019-11-14
Q2 2019 Unchanged 240,000 0 (0.0%) 75.87% $2,220,000 2019-08-14
Q1 2019 New 240,000 +240,000 (0.0%) 61.84% $1,543,000 2019-05-15

Who else reported the position

40 managers reported LA JOLLA PHARMACEUTICAL CO for Q3 2022.

Managers reporting LA JOLLA PHARMACEUTICAL CO in Q3 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ACADIAN ASSET MANAGEMENT LLC Reduced 0 -465,247 0 $0 7 qtrs
TANG CAPITAL MANAGEMENT LLC Reduced 0 -9,607,934 0 $0 35 qtrs
Schonfeld Strategic Advisors LLC Reduced 0 -15,500 0 $0 7 qtrs
Barclays PLC Reduced 0 -5,352 0 $0 25 qtrs
VANGUARD GROUP INC Reduced 0 -825,481 0 $0 33 qtrs
JPMorgan Chase & Co Reduced 0 -47 0 $0 20 qtrs
BlackRock Inc Reduced 0 -418,216 0 $0 30 qtrs
OLD NATIONAL BANCORP IN Reduced 0 -41,284 0 $0 2 qtrs
MEEDER ASSET MANAGEMENT INC Reduced 0 -3,867 0 $0 7 qtrs
RITHOLTZ WEALTH MANAGEMENT Reduced 0 -16,716 0 $0 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2022
Filed
November 14, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.